We are live on ! Find out more
PCM

Prelude Capital Management Portfolio holdings

AUM $1.31B
1-Year Est. Return 62.02%
This Fund
S&P 500
This Quarter Est. Return
+18.4%
1 Year Est. Return
+62.02%
3 Year Est. Return
+164.16%
5 Year Est. Return
+274.13%
10 Year Est. Return
+2,470.2%
AUM
$1.28B
AUM Growth
+$253M
Cap. Flow
+$143M
Cap. Flow %
11.17%
Top 10 Hldgs %
13.47%
Holding
1,446
New
471
Increased
321
Reduced
302
Closed
327

Top Buys

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$16.8M
2
U icon
Unity
U
+$14M
3
AIFC
AI Financial Corp
AIFC
+$13.8M
4
CYBR
CyberArk
CYBR
+$12.6M
5
NSC icon
Norfolk Southern
NSC
+$11.7M

Top Sells

Rank Stock Value
1
META icon
Meta Platforms (Facebook)
META
+$13.2M
2
TSLA icon
Tesla
TSLA
+$12.9M
3
BIDU icon
Baidu
BIDU
+$11.9M
4
HYG icon
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
+$10M
5
AMED
Amedisys
AMED
+$8.89M

Sector Composition

Rank Sector Weight
1 Technology 21.32%
2 Communication Services 11.38%
3 Healthcare 11.08%
4 Consumer Discretionary 10.37%
5 Financials 9.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UDMY
1076
DELISTED
Udemy
UDMY
$78.8K 0.01%
+11,236
New +$78.8K
GLUE icon
1077
Monte Rosa Therapeutics
GLUE
$1.35B
$75.6K 0.01%
+10,202
New +$54K
DAWN
1078
DELISTED
Day One Biopharmaceuticals
DAWN
$75K 0.01%
10,641
-8,898
-46% -$61.2K
HLX icon
1079
Helix Energy Solutions
HLX
$1.47B
$74.9K 0.01%
11,422
-13,978
-55% -$88K
BVS icon
1080
Bioventus
BVS
$1.17B
$73.5K 0.01%
+10,990
New +$76.3K
NOK icon
1081
Nokia
NOK
$51B
$72.5K 0.01%
15,075
-6,298
-29% -$28.5K
CLAR icon
1082
Clarus
CLAR
$145M
$72K 0.01%
20,560
-640
-3% -$2.31K
ULBI icon
1083
Ultralife
ULBI
$116M
$71.2K 0.01%
+10,441
New +$79.1K
ASPN icon
1084
Aspen Aerogels
ASPN
$521M
$70.4K 0.01%
+10,109
New +$71.3K
KRO icon
1085
KRONOS Worldwide
KRO
$977M
$70.1K 0.01%
12,206
-12,436
-50% -$75.3K
GDRX icon
1086
GoodRx Holdings
GDRX
$1.25B
$68.5K 0.01%
+16,200
New +$71.2K
EXFY icon
1087
Expensify
EXFY
$225M
$67.3K 0.01%
36,400
+14,800
+69% +$30K
QUAD icon
1088
Quad
QUAD
$507M
$66.9K 0.01%
10,684
-8,900
-45% -$54.8K
SGMO
1089
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$66.9K 0.01%
+99,316
New +$53.5K
VTYX
1090
DELISTED
Ventyx Biosciences
VTYX
$65.9K 0.01%
21,200
+5,500
+35% +$14.6K
CNDT icon
1091
Conduent
CNDT
$242M
$65.7K 0.01%
23,471
-8,415
-26% -$22.8K
DH icon
1092
Definitive Healthcare
DH
$73.7M
$63.7K 0.01%
+15,700
New +$62.7K
GANX icon
1093
Gain Therapeutics
GANX
$75.5M
$63.4K ﹤0.01%
35,820
– –
MQ icon
1094
Marqeta
MQ
$1.62B
$61.6K ﹤0.01%
+2,915
New +$69.1K
ABAT icon
1095
American Battery Technology Co
ABAT
$361M
$60.6K ﹤0.01%
+12,465
New +$32.6K
ABX
1096
Abacus Global Management
ABX
$913M
$59.9K ﹤0.01%
10,460
-594
-5% -$3.53K
ATAI icon
1097
AtaiBeckley Inc
ATAI
$2.68B
$59.7K ﹤0.01%
11,291
-9,454
-46% -$38.4K
BRY
1098
DELISTED
Berry Corp
BRY
$58.3K ﹤0.01%
15,411
-23,289
-60% -$75.5K
CNVS icon
1099
Cineverse
CNVS
$66M
$57.2K ﹤0.01%
17,037
+4,037
+31% +$20.1K
GUTS icon
1100
Fractyl Health
GUTS
$107M
$55.3K ﹤0.01%
+34,754
New +$45.1K
42 43
44
45 46

Similar funds

PFBT
Parkside Financial Bank & Trust Saint Louis, Missouri $1.31B AUM 19.14% 1-Year Est. Return
CCP
Clarkston Capital Partners Rochester, Michigan $1.31B AUM 3.79% 1-Year Est. Return
SP
Sherman Porfolios Coeur D'alene, Idaho $1.3B AUM 35.18% 1-Year Est. Return
HCS
Himension Capital (Singapore) Singapore $1.3B AUM 85.53% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
GPCM
Greenbrier Partners Capital Management Dallas, Texas $1.3B AUM 21.43% 1-Year Est. Return
MCM
Mainstay Capital Management Grand Blanc, Michigan $1.3B AUM 37.8% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Prelude Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Prelude Capital Management held 1,446 positions worth $1.28B, up 25% from $1.03B the previous quarter. Its ten largest holdings account for 13% of the portfolio.

Prelude Capital Management deployed $143M of net new capital in Q3 2025, opening 471 new positions and adding to 321 existing holdings. Its largest new stake was Verona Pharma: 160,565 shares worth $17.1M.

By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 19% a quarter earlier, followed by Communication Services and Healthcare.

On the sell side, the largest reduction was Meta Platforms (Facebook), an estimated $13.2M trimmed.

  • Prelude Capital Management's largest Q3 2025 buy was Verona Pharma: 160,565 shares worth $17.1M.
  • Prelude Capital Management added most to Amazon in Q3 2025, an estimated $11.4M increase.
  • Prelude Capital Management's biggest Q3 2025 reduction was Meta Platforms (Facebook), cutting an estimated $13.2M.
  • Prelude Capital Management fully exited Amedisys in Q3 2025, selling an estimated $8.89M.
  • Prelude Capital Management's ten largest holdings make up 13% of its $1.28B portfolio in Q3 2025.
  • Prelude Capital Management opened 471 new positions and closed 327 in Q3 2025.
  • Prelude Capital Management's portfolio value rose 25% quarter-over-quarter to $1.28B.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.